Objectives/Hypothesis: To examine the effect of dexamethasone on basal and proinflammatory cytokine-induced gelforming mucin expression in human middle ear epithelial cell line (HMEEC-1).
INTRODUCTION
Otitis media (OM) is a prevalent condition causing frequent pediatric office visits and antibiotic prescriptions. It afflicts most children and, as such, leads to extremely high expenditures of health care dollars globally. [1] [2] [3] [4] In countries with limited health care access, OM is the leading cause of preventable conductive hearing loss and is responsible for mortality due to otitisassociated complications. 5 In these areas where populations are challenged with treatment of OM, there exists an increased incidence of chronic ear conditions, which leads to permanent hearing loss and important lost opportunities for employment or economic advancement. 6, 7 Hearing loss associated with OM with effusion is also a difficulty in developed countries, with developmental delays and behavioral changes associated with the hearing loss. 8, 9 The substantial annual expenditure on OM treatments and its associated complications represent an important health care burden. 10 There is a critical need to understand OM pathogenesis and develop novel interventions aimed at reducing its health and socioeconomic burden.
Increased mucin secretion from the middle ear epithelium (MEE) is an important physiological event in OM. The production and secretion of mucins under normal physiological conditions provide the primary mucosal defense against pathogen incursion in OM. Dysregulation of mucus, or hypersecretion, is stimulated by both microbial-and host-derived factors and contributes significantly to OM pathogenesis. When mucin hypersecretion exists, the excessive production of mucin overloads the mechanisms of the host mucociliary clearance, resulting in accumulation of viscous fluid in the ME space and subsequent conductive hearing loss. There exists a need for data that examines the regulation of middle ear mucins in an attempt to appropriately design interventions that limit overproduction in cases that this leads to pathophysiology.
Secretory gel-forming mucin (GFM) genes are of particular interest in middle ear epithelial pathology. These are the major components contributing to the viscoelastic property of mucous secretion, characteristics that can compromise the normal mucociliary clearance and epithelial defense mechanisms. The GFMs identified in human middle ear includes MUC2, MUC5AC, MUC5B, and MUC19.
11 MUC2 and MUC5AC are produced by goblet and basal cells of surface epithelium, whereas MUC5B and MUC19 are glandular mucins detected mainly in submucosal glands. Studies have demonstrated each of these mucins to be upregulated by proinflammatory cytokines and major pathogenic middle ear bacteria. [12] [13] [14] Among these, MUC2, MUC5AC, and MUC5B upregulation were demonstrated in middle ear mucosa of children with OM, suggesting their critical roles in OM pathogenesis. [15] [16] [17] The current investigation provides a novel data set examining mucin regulation with dexamethasone in human MEE. The study design was specifically chosen given the ready availability of this medication, which already has Food and Drug Association (FDA) approval for use in the middle ear. In particular, recent advances in the production of sustained-release preparations of otic steroid medications make steroids a particularly interesting area of study for patients with difficulties from chronic OM.
MATERIALS AND METHODS

Cell Culture
A culture model of human middle ear epithelial cell line (HMEEC-1) (initial generous gift by Dr. David J Lim) was an immortalized cell line whose primary characterization regarding transformation and growth properties has been published. 18 The culture was maintained in a humidified atmosphere at 378C, with 5% CO 2 in full-growth media containing a 1:1 ratio mixture of Dulbecco's Modified Eagle Medium (ThermoFisher Scientific, Grand Island, NY), Bronchial Epithelial Cell Basal Medium (Lonza, Allendale, NJ), 10% fetal bovine serum (ATCC, Manassas, VA), and 1% Antibiotic-Antimycotic (containing penicillin, streptomycin and Fungizone by Life Technologies)-and supplemented with one bag of BEGM Singlequots (Lonza) for every 500 mL portion of the media.
Proinflammatory Cytokine-Induced Mucin Expression
The culture maintained in full growth media was serumstarved overnight and subsequently exposed to 200 ng/mL tumor necrosis factor-alpha (TNF-a) (R&D Systems) or 100 ng/mL interleukin-1 beta (IL-1b) (R&D Systems, Minneapolis, MN) for 1, 2, 4, and 8 hours. The optimal time point that provided the highest response of mucin gene was tested with culture exposed to various concentrations of the cytokines in basal media containing supplements. Cell lysate was harvested at the end of exposure time.
Effect of Dexamethasone on Mucin Expression
HMEEC-1 in full growth media generally produced mucin at about the level of detection by quantitative polymerase chain reaction (qPCR). The examination of steroid-inhibiting effect will result in greater threshold cycles than the qPCR detection limit (> 35 cycles), hence the cells were grown in the presence of 1 lM retinoic acid (RA) (Sigma) for 5 days prior to treatment to enhance the overall level of transcriptional mucin gene expression. To determine a steroid impact on mucin expression, hydrocortisone (as part of BEGM Singlequots [Lonza] supplement) was removed from the culture media 48 hours prior to treatment with dexamethasone to ensure that there were no confounding impacts from the culture media. To examine the effect of dexamethasone on the steady state level of MUC5AC, the culture was serum-starved overnight and subsequently treated with 10 lM dexamethasone for 2, 4, 8, 16, and 24 hours in basal media (containing supplements and 1 lM RA) for a time-course exposure. For dose-dependent experiment, the culture was treated with dexamethasone at 0.00001, 0.001, 0.1, and 10 lM final concentrations in the basal media. To examine the effect of dexamethasone on proinflammatory cytokinesinduced mucin expression, the optimal condition for each mucin gene response to the specific cytokine was tested with culture in the presence of 10 lM dexamethasone. Nontreated control cells for both time-and dose-dependent experiments were handled in the same manner as treated cells. Cell lysate was harvested at the end of exposure time.
Quantitative PCR
Total RNA from experimental cultures was prepared after the indicated treatments using TRIzol reagent (ThermoFisher Scientific). Complementary DNA was synthesized using the SuperScript III First-Strand Synthesis System (ThermoFisher Scientific). Each cDNA reaction prepared for proinflammatory cytokine-induced mucin experiments required 2 lg starting total RNA to detect each specific mucin. For the study of dexamethasone effect on mucin expression, a 0.4 lg of starting total RNA was sufficient for cDNA preparation. Quantitative PCR was carried out on a ViiA7 by ThermoFisher Scientific using their commercially available TaqMan primer probes for MUC2 (part number:
Hs00159374_m1), MUC5AC (part number: Hs00873651_mH), and HPRT1 (part number: Hs99999909_m1). Samples were analyzed in triplicate, and a no template control was included for each gene. The expression levels of each of the targeted mucin genes detected by qPCR were normalized to the mRNA level of the housekeeping gene HPRT1. The relative fold change of mucin gene was calculated using 2 2DDCt methodology. 19 
Statistics
All experiments were performed in triplicate. The results were presented as mean 6 standard error of means. Data of the time course studies were analyzed by Student's t test. Differences in mucin gene expression to multiple concentrations of various substances were determined by one-way analysis of variance followed by Tukey's post-hoc. All statistical analyses were performed using Prism 5.01 software (GraphPad Software, Inc, La Jolla, CA).
RESULTS
Proinflammatory Cytokines Induce Gel-Forming Mucin Gene Expression in HMEEC-1
HMEEC-1 exposed to TNF-a displayed a demonstrable increase in MUC2 expression at 4-and 8-hour time points (P 5 0.005 and 0.011, respectively). The culture exposed to TNF-a at various concentrations at the optimal time point of 4 hours demonstrated a significant increase of MUC2 (P < 0.0001), with a greater than three-fold increase in transcript expression compared with control at 200 ng/mL of TNF-a (Fig. 1A-B ). Higher levels of induction were observed in the level of MUC5AC where significant response was observed as early as at 2 hours (P 5 0.049) and continued at 4 and 8 hours with P 5 0.003 and 0.014, respectively (Fig. 1C) . With the 4-hour time point as a constant variable, HMEEC-1 exposed to TNF-a displayed a significant increase in MUC5AC expression (P 5 0.008). The optimal concentration of 50 mg/mL TNF-a increased MUC5AC transcript just under four times that of the control (Fig. 1D) . The response of each GFM to various concentrations of TNF-a was not linear and failed to increase mucin expression at the higher dosages.
Similar upregulation for the two GFM genes was demonstrated in the HMEEC-1 exposed to IL-1b. Utilizing the time as a dependent variable, the 2-hour exposure time point was significantly different than other time points (P 5 0.007) in stimulating MUC2 transcript ( Fig. 2A) . When the culture was exposed to various concentrations of IL-1b for 2 hours, the significant increase of MUC2 level was observed at all concentrations (Fig. 2B) (P 5 0.0004). The level of induction was not linear in that it plateaued at the higher dosage of IL-1b. MUC5AC response was two-to four-fold greater than the control at 2, 4, and 8 hours with P value of 0.036, 0.0003, and 0.016, respectively. Nonlinear increase of MUC5AC was observed when IL-1b dosage varied. The exposure to 50 ng/mL IL-1b demonstrated a three-fold increase of MUC5AC expression compared to the control (P 5 0.019). The 50 ng/mL of IL-1b was the optimal concentration that provided the significant increase of both mucin transcripts.
Dexamethasone Reduces Steady-State Level of Gel-Forming Mucin Genes
The effect of dexamethasone on steady-state level of GFM was demonstrated in Figure 3 . Dexamethasone significantly inhibited MUC5AC transcript in HMEEC-1 in a time-dependent manner. A greater than 50% reduction of MUC5AC expression was observed at every time point tested (P < 0.05). At 4 hours of exposure, the effective DEX concentrations ranged from 0.001 to 10 lM. MUC2 was effectively suppressed at all time points tested (P < 0.05) (Fig. 3C) . There existed the temporal difference in DEX suppression of basal MUC2 and MUC5AC. The basal levels of MUC5AC were reduced by greater than 50% in the first 2 hours, whereas MUC2 transcripts were reduced by half after 16 hours of exposure.
Dexamethasone Inhibits Proinflammatory Cytokine-Induced Mucin Expression
To validate the effect of dexamethasone on proinflammatory cytokine-induced mucin expression, it is important to measure impact at the greatest level of mucin production to maximally determine the impact of the dexamethasone intervention. Therefore, HMEEC-1 Fig. 1 . TNF-a-induces gel-forming mucin gene expression in HMEEC-1. The culture of HMEEC-1 was exposed to 200 ng/mL TNF-a at various time points. Both MUC2 (A) and MUC5AC (C) were upregulated. The response to various dosage of TNF-a was conducted at the optimal exposure of 4 hours for both MUC2 (B) and MUC5AC (D). Bar represent mean 6 standard error of the mean. *P < 0.05 vs. control. HMEEC-1 5 human middle ear epithelial cell line; TNF-a 5 tumor necrosis factor-alpha.
was exposed to each specific cytokine (TNF-a and IL-1b) in the presence of dexamethasone at its optimal conditions. Dexamethasone effectively reversed the TNF-ainduced MUC2 and MUC5AC expression to basal level (Fig. 4A) . Similar significant inhibition effect was obtained with IL-1b-induced mucin expression for both MUC2 and MUC5AC (Fig. 4B) .
DISCUSSION
The mucosal epithelium in the middle ear is similar to that found in other areas of the human respiratory tract. Common to all anatomic areas where this respiratory epithelium is found is a need to act as a protective barrier to underlying tissues from damage and injury induced by bacterial and viral pathogens. In addition, other causes of middle ear epithelial injury and inflammation have been studied, including environmental agents such as tobacco smoke or internal agents such as pepsin. [20] [21] [22] When confronted with potential injury from such agents, this respiratory epithelium undergoes predictable responses regardless of the potential offending agent. This response includes mucosal hypertrophy, goblet cell proliferation, and an increase in the production of GFMs. [23] [24] [25] Our previous investigations, as well as others, 12, 13, 26, 27 have demonstrated that a generalizable model for inflammation in the middle ear is a model that examines the upstream inflammatory signaling cascade, which leads to production of increased GFMs. This cascade includes the inflammatory cytokines TNF-a and IL-1b. Glucocorticoid ability to limit Muc2 transcripts has been demonstrated in a murine xenograft model of human pseudomyxoma peritonei. 28 Others have demonstrated a repression of MUC5AC induction by bacteria or chemokines in other respiratory epithelial cell lines with the use of glucocorticoids. [29] [30] [31] This investigation is the first to examine the impact of a glucocorticoid on the production of both GFMs, MUC5AC, and MUC2 in a human middle ear model, and to demonstrate its impact on basal levels of mucin transcripts in a human middle ear model.
The results of this investigation add to the growing literature that glucocorticoids are promising agents for the regulation of mucin production by middle ear mucosa. Importantly, this current data set is also not limited to a specific agent that may underlie MEE mucosal inflammatory events. Otitis media is known to be a multifactorial process, with many infections having multiple bacteria present or mixed bacterial and viral etiologies. [32] [33] [34] Additional investigations have also linked other agents such as gastroesophageal reflux 22 and tobacco smoke 20 to predisposition to OM through inflammatory mediated events. A number of studies, including those from our laboratory, have examined the signaling pathways of inflammation in OM. 13, 26, 27, [35] [36] [37] Not surprisingly, given the ubiquitous presence of TNF-a and IL-1b in upstream cascades of mammalian inflammatory pathways, these inflammatory cytokines have been demonstrated to be critical in the signaling pathways of inflammatory events leading to mucin gene upregulation and mucin production in human MEE. Therefore, we examined these two particular inflammatory cytokines as an upstream generalizable model of middle ear inflammation. Using a generalizable model of inflammation creates an ability to surmise that inhibiting the inflammatory process upstream, as we have done in these experiments, will provide information regarding the modulation of mucin production from a large variety of insults, which may contribute to mucin hypersecretion and ultimately hearing loss or other complications in OM.
The effect of TNF-a and IL-1b on MUC5AC expression was not linear because it failed to increase the expression at higher dosage. For these types of in vitro experiments, it is not uncommon to have some lack of Fig. 3 . Effect of dexamethasone on the basal expression of gelforming mucin genes. Gel-forming mucin transcripts were assessed in human middle ear epithelial cell line exposed to 10 lM DEX at various time points. Dexamethasone reduced the basal expression of MUC5AC transcripts (A). At 4-hour exposure, DEX effectively reduced MUC5AC at concentration range from 0.00001 to 10 lM (B). The temporal difference between DEX suppression of basal MUC2 and MUC5AC was demonstrated (C). Bar represents mean 6 standard error of the mean. *P < 0.05 vs. control. DEX 5 dexamethasone. linear relationship to dosage, particularly at higher levels. 38 The lack of linear response may be due to the cytokine incapacity to access a saturable receptormediated transport process and/or response of the target epithelial cells. The bell-shaped response curve may be associated with a signal transduction mechanism in which the cells become resistant to the downstream receptor-mediated stimulation. There also exist negative feedback mechanisms in these signaling pathways that may result in nonlinear response.
The treatment times for TNF-a and IL-1b were chosen related to maximum expression of the mucin genes being examined in relationship to the inflammatory cytokines. From an in vivo perspective, it is important to acknowledge that the inflammatory pathways related to any potential middle ear infectious process will be heterogeneous and dependent on both host-and pathogenspecific conditions. Therefore, any specific treatment in the middle ear with an agent such as dexamethasone will likely require an ability to pharmacologically interact with the middle ear mucosa over a period of time, something that could be achieved with sustained-release agents.
As we have discussed previously, 11 it is also important to examine the impact of inflammatory responses on a variety of gel-forming or secretory mucins, which include both MUC5AC and MUC2. In experiments conducted in our laboratory and elsewhere, each of the GFMs have been demonstrated to have upregulation in the presence of generalized inflammatory agents TNF-a and IL-1b, as well as in more specific inflammatory experiments using specific pathogens. 14, 39 The precise function and role of these GFMs in response to various stimuli has yet to be elucidated. However, this will be an important area of investigation in the future. What is clear from this current investigation is that, in our generalizable model of HMEEC-1 inflammation, the GFMs of MUC5AC and MUC2 have a differential response to inflammation and regulation by dexamethasone. However, the inflammatory events that lead to increased production of these GFMs is reversed by the glucocorticoid dexamethasone in a dose-and time-dependent fashion.
In addition, we examined the ability of dexamethasone to reduce the baseline production of the GFMs. In these experiments, the basal levels of both MUC2 and MUC5AC were reduced by greater than 50%. The temporal difference between dexamethasone suppression of either mucin genes was demonstrated as well. This is an important consideration because basal levels of production of mucins are important in the overall protective mechanisms of respiratory epithelium. As such, any attempt to regulate MEE mucin production must recognize these positive functions of mucins and will need to consider what might be the optimal level of downregulation of production.
In patients with chronic OM, our laboratory has demonstrated significant upregulation of mucin gene from middle ear biopsies taken at the time of tympanostomy tube insertion. 15, 16 These patients often have middle ear effusions and hearing loss as their predisposing pathology, necessitating surgery. In clinical trials, our laboratory has also demonstrated that these patients with chronic OM with middle ear effusion have an increased risk of complications following their tympanostomy tube insertion if they are not treated postoperatively with middle ear drops containing a steroid and antibiotic. 40 These complications can be significant because they can lead to plugging of the tympanostomy tube or persistent drainage from the tympanostomy tube. As such, it is common practice to use these otic drops following surgery in children with middle ear effusions. It has been postulated that the glucocorticoid in these otic drops is important. Particularly, the addition of 0.1% dexamethasone to 0.3% ciprofloxacin has been shown to increase treatment success rate and effectiveness in eradication of pathogens more than formulations containing antibiotics alone. 41, 42 Recent advances in sustained-release otic preparations hold promise to simplify the beneficial impact of glucocorticoid preparations. These sustained-release compounds provide a potential intraoperative use and thereby limit the need for repeated dosing by parents. Importantly, the rate of release of these preparations can be modified to create a specified dosing regimen to modulate middle ear inflammation in a predictable fashion. Perhaps most significantly, in the future these preparations may provide a potential for delivery to reverse the detrimental impact of mucosal inflammation and hypertrophy, as well as its associated mucin hypersecretion, without the need for surgical placement of tympanostomy tubes. [43] [44] [45] Given the difficulty of delivery through an intact tympanic membrane, the potential to achieve this is currently under investigation. In patients with chronic OM and nonintact tympanic membranes, there exists a more ready avenue for this type of therapeutic intervention. With this possibility of modulating the middle ear inflammatory responses, understanding precise dose and MEE responses to intervention and temporal changes will be critical. The data set presented here gives an early indication of some of the parameters that warrant consideration as these experiments are designed and move forward.
CONCLUSION
In conclusion, the experiments presented in this article provide a conclusive picture of the ability to use glucocorticoids to downregulate mucin gene expression and production in human MEE with a generalizable model of inflammation that is applicable to multiple potential causes of MEE mucosal hypertrophy. This data adds to the promising potential of future interventions for patients with chronic OM.
